Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nephros (NEPH) EBITDA (2016 - 2025)

Nephros (NEPH) has 16 years of EBITDA data on record, last reported at $314000.0 in Q3 2025.

  • For Q3 2025, EBITDA rose 52.43% year-over-year to $314000.0; the TTM value through Sep 2025 reached $1.4 million, up 254.71%, while the annual FY2024 figure was $6000.0, 100.38% up from the prior year.
  • EBITDA reached $314000.0 in Q3 2025 per NEPH's latest filing, up from $248000.0 in the prior quarter.
  • Across five years, EBITDA topped out at $566000.0 in Q1 2025 and bottomed at -$3.4 million in Q3 2022.
  • Average EBITDA over 5 years is -$616157.9, with a median of -$433000.0 recorded in 2023.
  • Peak YoY movement for EBITDA: plummeted 262.8% in 2022, then surged 434.91% in 2025.
  • A 5-year view of EBITDA shows it stood at -$1.3 million in 2021, then surged by 49.14% to -$653000.0 in 2022, then dropped by 0.15% to -$654000.0 in 2023, then skyrocketed by 148.47% to $317000.0 in 2024, then fell by 0.95% to $314000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were $314000.0 in Q3 2025, $248000.0 in Q2 2025, and $566000.0 in Q1 2025.